Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Oncologic Trends, Outcomes, and Risk Factors for Locoregional Recurrence: An Analysis of Tumor-to-Nipple Distance and Critical Factors in Therapeutic Nipple-Sparing Mastectomy

Frey, Jordan D. M.D.; Salibian, Ara A. M.D.; Lee, Jiyon M.D.; Harris, Kristin D.O.; Axelrod, Deborah M. M.D.; Guth, Amber A. M.D.; Shapiro, Richard L. M.D.; Schnabel, Freya R. M.D.; Karp, Nolan S. M.D.; Choi, Mihye M.D.

Plastic and Reconstructive Surgery: June 2019 - Volume 143 - Issue 6 - p 1575-1585
doi: 10.1097/PRS.0000000000005600
Breast: Original Articles
Buy
Discussion
Patient Safety CME

Background: Oncologic outcomes with nipple-sparing mastectomy continue to be established. The authors examine oncologic trends, outcomes, and risk factors, including tumor-to-nipple distance, in therapeutic nipple-sparing mastectomies.

Methods: Demographics, outcomes, and overall trends for all nipple-sparing mastectomies performed for a therapeutic indication from 2006 to 2017 were analyzed. Oncologic outcomes were investigated with specific focus on recurrence and associated factors, including tumor-to-nipple distance.

Results: A total of 496 therapeutic nipple-sparing mastectomies were performed, with an average follow-up time of 48.25 months. The most common tumor types were invasive carcinoma (52.4 percent) and ductal carcinoma in situ (50.4 percent). Sentinel lymph node sampling was performed in 79.8 percent of nipple-sparing mastectomies; 4.1 percent had positive frozen sentinel lymph node biopsy results, whereas 15.7 percent had positive nodal status on permanent pathologic examination. The most common pathologic cancer stage was stage IA (42.5 percent) followed by stage 0 (31.3 percent). The rate of local recurrence was 1.6 percent (n = 8), and the rate of regional recurrence was 0.6 percent (n = 3). In all, 171 nipple-sparing mastectomies had magnetic resonance imaging available with which to assess tumor-to-nipple distance. Tumor-to-nipple distance of 1 cm or less (25.0 percent versus 2.4 percent; p = 0.0031/p = 0.1129) and of 2 cm or less (8.7 percent versus 2.0 percent; p = 0.0218/p = 0.1345) trended to higher rates of locoregional recurrence. In univariate analysis, tumor-to-nipple distance of 1 cm or less was the only significant risk factor for recurrence (OR, 13.5833; p = 0.0385). No factors were significant in regression analysis.

Conclusions: In early stage and in situ breast carcinoma, therapeutic nipple-sparing mastectomy appears oncologically safe, with a locoregional recurrence rate of 2.0 percent. Tumor-to-nipple distances of 1 cm or less and 2 cm or less trended to higher recurrence rates.

CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

Patient Safety CME.

New York, N.Y.

From the Hansjörg Wyss Department of Plastic Surgery and the Departments of Radiology and Surgery, New York University Langone Health.

Received for publication June 8, 2018; accepted October 19, 2018.

Disclosure:The authors have no financial interest to declare in relation to the content of this article.

By reading this article, you are entitled to claim one (1) hour of Category 2 Patient Safety Credit. ASPS members can claim this credit by logging in to PlasticSurgery.org Dashboard, clicking “Submit CME,” and completing the form.

Mihye Choi, M.D., New York University Langone Health, 305 East 47th Street, Suite 1A, New York, N.Y. 10017, mihye.choi@nyumc.org, Instagram: @choim01, @JordanFreyMD, @AraSalibianMD, @NolanKarp, Twitter: @choim01, @JordanFreyMD, @AraSalibianMD, @NolanKarp

Copyright © 2019 by the American Society of Plastic Surgeons